Improved Estimations Of Cost-Effectiveness For Ovarian Cancer

Published May 17, 2013
High Wycombe, UK - Improvements in ovarian cancer survival rates have been modest with a median survival after recurrence of just two years. Patients with disease relapsing more than six months after completion of a platinum chemotherapy regimen are said to have platinum-sensitive disease, where a host of platinum and non-platinum alternatives are considered. Final survival results have become available for trabectedin plus PLDH in the treatment of relapsed platinum-sensitive ovarian cancer. A study, “Cost-Effectiveness of Trabectedin Plus Pegylated Liposomal Doxorubicin for the Treatment of Women with Relapsed Platinum-Sensitive Ovarian Cancer in the UK: Analysis Based on the Final Survival Data of the OVA-301 Trial,” published in Value in Health, is the first study to estimate the costs and QALYs of treatment based on the final survival data, and is therefore critical to inform accurate estimations of cost-effectiveness. Survival analysis showed that adjusting for imbalances in prognostic factors including the time between platinum regimen initiation and relapse (also known as the platinum-free interval) significantly improved goodness-of-fit when estimating average patient survival time. Results from the decision analytic model improved survival with trabectedin plus PLDH compared to PLDH alone, and an ICER of £38,026 per QALY. This could significantly impact cost-effectiveness conclusions in the UK for patients who are not expected to benefit from treatment with platinum-based therapies. Mark Fisher, MSc, Health Economics Manager at WG Consulting and lead author of the study, states, "The final analysis estimated a significant improvement in survival and cost-effectiveness outcomes compared to that originally calculated based on an interim analysis of immature survival data."

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information:

Related Stories

Measuring What Matters: Broadening the Scope of Health Economics Evaluation to Incorporate Well-Being

Jul 9, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health that offer insights into facets of economic evaluation aimed to incorporate well-being into decision making.

Confronting the Backlash Against QALYs: Key Insights From Leading Health Economists

Jun 18, 2024

ISPOR announced the publication of a collection of papers that examine the long-standing debate surrounding the use of quality-adjusted life years (QALYs) and alternative measures in healthcare decision making.

ISPOR Good Practices Report Offers Guidance for Using Real-World Data From EHRs in Health Technology Assessments

Jun 17, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that proposes a framework for assessing the suitability of electronic health records data for use in health technology assessments. The report, “Assessing Real-World Data from Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force” was published in the June 2024 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now